EP Patent

EP3909966A1 — 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy

Assigned to Sage Therapeutics Inc · Expires 2021-11-17 · 4y expired

What this patent protects

According to the present application, there is provided the compound of the formula indicated herein or a pharmaceutically acceptable salt thereof in the treatment in humans of bipolar disorder, anxiety disorder, depression, tremor or tinnitus.

USPTO Abstract

According to the present application, there is provided the compound of the formula indicated herein or a pharmaceutically acceptable salt thereof in the treatment in humans of bipolar disorder, anxiety disorder, depression, tremor or tinnitus.

Drugs covered by this patent

Patent Metadata

Patent number
EP3909966A1
Jurisdiction
EP
Classification
—
Expires
2021-11-17
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.